Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL27529277 | 0.86 | MMP8 (0.49) | TSHRALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL6154370 | 0.83 | MMP8 (0.51) | CYP19A1NAMPTTSHRALDH1A1CDC7 | |
| SCHEMBL5983555 | 0.81 | MMP8 (0.57) | TSHRLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL3279844 | 0.81 | KMT2A (0.47) | TSHRALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL11262091 | 0.81 | CYP19A1 (0.57) | CYP19A1CYP17A1TSHRLMNAKMT2A | |
| SCHEMBL304815 | 0.81 | MMP8 (0.57) | TSHRLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL10756249 | 0.81 | MMP8 (0.57) | TSHRLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL12896270 | 0.81 | CYP19A1 (0.57) | CYP19A1CYP17A1TSHRLMNAKMT2A | |
| SCHEMBL7799722 | 0.80 | KMT2A (0.39) | TSHRALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL17086147 | 0.80 | NAMPT (0.44) | CYP19A1NAMPTALDH1A1CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462661-A | Deuterated 3- (pyridin-4-yl) propionic acid compound, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-115666554-A | Novel Maxi-K potassium channel openers for the treatment of fragile X related disorders | 凯鲁斯生物科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-104428293-B | Adjust the benzimidazole of TNF α | UCB生物制药私人有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| EP-0694545-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | SEARLE & CO (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0911331-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5576315-A | Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia | G.D. SEARLE & CO. (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0694546-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0694545-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5464830-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5378840-A | Substituted dibenzoxazepine compounds | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0583421-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | CYP19A1 4235/4885NAMPT 1624/4885CYP17A1 2795/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP19A1 4211/4885NAMPT 1562/4885CYP17A1 3002/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP19A1 4211/4885NAMPT 1562/4885CYP17A1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.